Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| FATE THERAPEUTICS INCFATE · Entity 5968 | Chief Scientific Officer | March 08, 2021 | March 09, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
FATE THERAPEUTICS INC
Report date March 08, 2021 · Filed March 09, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common stockSEC Table I · non-derivative | Direct | 73,020 |
Ending reported balance
After 2021-03-08 transaction · row 8
8 source rows · reconciled sequenceRow 1 · 2021-03-08 · Sale · Disposed 3,298 · Balance 94,722 F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 12, 2020. F2: Represents the weighted average sale price of the shares sold ranging from $78.08 to $79.02 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price. Row 2 · 2021-03-08 · Sale · Disposed 4,627 · Balance 90,095 F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 12, 2020. F3: Represents the weighted average sale price of the shares sold ranging from $79.09 to $80.08 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price. Row 3 · 2021-03-08 · Sale · Disposed 5,174 · Balance 84,921 F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 12, 2020. F4: Represents the weighted average sale price of the shares sold ranging from $80.12 to $81.09 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price. Row 4 · 2021-03-08 · Sale · Disposed 2,993 · Balance 81,928 F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 12, 2020. F5: Represents the weighted average sale price of the shares sold ranging from $81.19 to $82.15 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price. Row 5 · 2021-03-08 · Sale · Disposed 2,480 · Balance 79,448 F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 12, 2020. F6: Represents the weighted average sale price of the shares sold ranging from $82.74 to $83.68 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price. Row 6 · 2021-03-08 · Sale · Disposed 2,728 · Balance 76,720 F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 12, 2020. F7: Represents the weighted average sale price of the shares sold ranging from $83.775 to $84.76 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price. Row 7 · 2021-03-08 · Sale · Disposed 2,900 · Balance 73,820 F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 12, 2020. F8: Represents the weighted average sale price of the shares sold ranging from $84.99 to $85.81 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price. Row 8 · 2021-03-08 · Sale · Disposed 800 · Balance 73,020 F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 12, 2020. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 12, 2020.
F2: Represents the weighted average sale price of the shares sold ranging from $78.08 to $79.02 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price.
F3: Represents the weighted average sale price of the shares sold ranging from $79.09 to $80.08 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price.
F4: Represents the weighted average sale price of the shares sold ranging from $80.12 to $81.09 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price.
F5: Represents the weighted average sale price of the shares sold ranging from $81.19 to $82.15 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price.
F6: Represents the weighted average sale price of the shares sold ranging from $82.74 to $83.68 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price.
F7: Represents the weighted average sale price of the shares sold ranging from $83.775 to $84.76 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price.
F8: Represents the weighted average sale price of the shares sold ranging from $84.99 to $85.81 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 08, 2021 Filed Mar 9, 2021 21:02 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon stock | 800 | $86.70 | $69,360.00 |
DisclosureSEC source: 0001209191-21-018932 · doc4.xml · nonDerivative · entry 8 Shoemaker Daniel D · CIK 0001586892 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,020 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 12, 2020. Read SEC document |
| March 08, 2021 Filed Mar 9, 2021 21:02 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon stock | 2,900 | $85.50 | $247,956.09 |
DisclosureSEC source: 0001209191-21-018932 · doc4.xml · nonDerivative · entry 7 Shoemaker Daniel D · CIK 0001586892 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,820 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 12, 2020. F8 · price: Represents the weighted average sale price of the shares sold ranging from $84.99 to $85.81 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price. Read SEC document |
| March 08, 2021 Filed Mar 9, 2021 21:02 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon stock | 2,728 | $84.20 | $229,704.69 |
DisclosureSEC source: 0001209191-21-018932 · doc4.xml · nonDerivative · entry 6 Shoemaker Daniel D · CIK 0001586892 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,720 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 12, 2020. F7 · price: Represents the weighted average sale price of the shares sold ranging from $83.775 to $84.76 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price. Read SEC document |
| March 08, 2021 Filed Mar 9, 2021 21:02 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon stock | 2,480 | $83.46 | $206,989.48 |
DisclosureSEC source: 0001209191-21-018932 · doc4.xml · nonDerivative · entry 5 Shoemaker Daniel D · CIK 0001586892 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,448 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 12, 2020. F6 · price: Represents the weighted average sale price of the shares sold ranging from $82.74 to $83.68 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price. Read SEC document |
| March 08, 2021 Filed Mar 9, 2021 21:02 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon stock | 2,993 | $81.60 | $244,224.31 |
DisclosureSEC source: 0001209191-21-018932 · doc4.xml · nonDerivative · entry 4 Shoemaker Daniel D · CIK 0001586892 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,928 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 12, 2020. F5 · price: Represents the weighted average sale price of the shares sold ranging from $81.19 to $82.15 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price. Read SEC document |
| March 08, 2021 Filed Mar 9, 2021 21:02 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon stock | 5,174 | $80.73 | $417,722.37 |
DisclosureSEC source: 0001209191-21-018932 · doc4.xml · nonDerivative · entry 3 Shoemaker Daniel D · CIK 0001586892 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,921 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 12, 2020. F4 · price: Represents the weighted average sale price of the shares sold ranging from $80.12 to $81.09 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price. Read SEC document |
| March 08, 2021 Filed Mar 9, 2021 21:02 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon stock | 4,627 | $79.58 | $368,235.63 |
DisclosureSEC source: 0001209191-21-018932 · doc4.xml · nonDerivative · entry 2 Shoemaker Daniel D · CIK 0001586892 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,095 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 12, 2020. F3 · price: Represents the weighted average sale price of the shares sold ranging from $79.09 to $80.08 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price. Read SEC document |
| March 08, 2021 Filed Mar 9, 2021 21:02 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon stock | 3,298 | $78.60 | $259,235.66 |
DisclosureSEC source: 0001209191-21-018932 · doc4.xml · nonDerivative · entry 1 Shoemaker Daniel D · CIK 0001586892 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,722 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 12, 2020. F2 · price: Represents the weighted average sale price of the shares sold ranging from $78.08 to $79.02 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price. Read SEC document |
| January 20, 2021 Filed Jan 22, 2021 23:19 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | GrantStock Option (right to buy) · Derivative | 5,481 | Not disclosed Strike: $109.01 | Not disclosed |
DisclosureSEC source: 0001209191-21-004954 · doc4.xml · derivative · entry 2 Shoemaker Daniel D · CIK 0001586892 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,481 Underlying: Common Stock · 5,481 shares Expires 2031-01-20 F3 · price: Not applicable. F2 · derivative.exercise_date: The shares subject to this option shall vest in 48 equal monthly installments beginning on February 1, 2021 such that this option is fully exercisable on January 1, 2025. Read SEC document |
| January 20, 2021 Filed Jan 22, 2021 23:19 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | GrantCommon stock | 14,411 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-004954 · doc4.xml · nonDerivative · entry 1 Shoemaker Daniel D · CIK 0001586892 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,020 F1 · security: Award of restricted stock units ("RSUs") that vests with respect to the 1/4th of the underlying shares on each of January 8, 2022, January 8, 2023, January 8, 2024, and January 8, 2025. Read SEC document |
| January 11, 2021 Filed Jan 13, 2021 01:38 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon stock | 871 | $109.65 | $95,508.63 |
DisclosureSEC source: 0001209191-21-003338 · doc4.xml · nonDerivative · entry 7 Shoemaker Daniel D · CIK 0001586892 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,609 F6 · shares: Required number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of 6,250 shares of Common Stock underlying RSUs granted to the reporting person on January 8, 2020. This sale was made pursuant to an irrevocable election by the reporting person to satisfy tax withholding obligations through a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F9 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $109.19 to $110.18 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 11, 2021 Filed Jan 13, 2021 01:38 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon stock | 1,050 | $110.76 | $116,295.90 |
DisclosureSEC source: 0001209191-21-003338 · doc4.xml · nonDerivative · entry 6 Shoemaker Daniel D · CIK 0001586892 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,480 F6 · shares: Required number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of 6,250 shares of Common Stock underlying RSUs granted to the reporting person on January 8, 2020. This sale was made pursuant to an irrevocable election by the reporting person to satisfy tax withholding obligations through a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F8 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.19 to $111.18 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 11, 2021 Filed Jan 13, 2021 01:38 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon stock | 1,332 | $111.62 | $148,672.51 |
DisclosureSEC source: 0001209191-21-003338 · doc4.xml · nonDerivative · entry 5 Shoemaker Daniel D · CIK 0001586892 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,530 F6 · shares: Required number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of 6,250 shares of Common Stock underlying RSUs granted to the reporting person on January 8, 2020. This sale was made pursuant to an irrevocable election by the reporting person to satisfy tax withholding obligations through a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F7 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $111.19 to $112.18 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 08, 2021 Filed Jan 13, 2021 01:38 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon stock | 151 | $114.76 | $17,328.01 |
DisclosureSEC source: 0001209191-21-003338 · doc4.xml · nonDerivative · entry 4 Shoemaker Daniel D · CIK 0001586892 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,862 F1 · shares: Required number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of 15,000 shares of Common Stock underlying RSUs granted to the reporting person on January 7, 2019. This sale was made pursuant to an irrevocable election by the reporting person to satisfy tax withholding obligations through a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F5 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $114.38 to $115.37 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 08, 2021 Filed Jan 13, 2021 01:38 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon stock | 872 | $115.80 | $100,976.73 |
DisclosureSEC source: 0001209191-21-003338 · doc4.xml · nonDerivative · entry 3 Shoemaker Daniel D · CIK 0001586892 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,013 F1 · shares: Required number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of 15,000 shares of Common Stock underlying RSUs granted to the reporting person on January 7, 2019. This sale was made pursuant to an irrevocable election by the reporting person to satisfy tax withholding obligations through a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $115.38 to $116.37 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 08, 2021 Filed Jan 13, 2021 01:38 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon stock | 2,451 | $117.15 | $287,144.45 |
DisclosureSEC source: 0001209191-21-003338 · doc4.xml · nonDerivative · entry 2 Shoemaker Daniel D · CIK 0001586892 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,885 F1 · shares: Required number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of 15,000 shares of Common Stock underlying RSUs granted to the reporting person on January 7, 2019. This sale was made pursuant to an irrevocable election by the reporting person to satisfy tax withholding obligations through a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $116.38 to $117.37 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 08, 2021 Filed Jan 13, 2021 01:38 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon stock | 2,755 | $117.60 | $323,985.25 |
DisclosureSEC source: 0001209191-21-003338 · doc4.xml · nonDerivative · entry 1 Shoemaker Daniel D · CIK 0001586892 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,336 F1 · shares: Required number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of 15,000 shares of Common Stock underlying RSUs granted to the reporting person on January 7, 2019. This sale was made pursuant to an irrevocable election by the reporting person to satisfy tax withholding obligations through a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $117.38 to $118.37 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 16, 2020 Filed Nov 16, 2020 22:12 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon stock | 14,781 | $52.40 | $774,514.05 |
DisclosureSEC source: 0001209191-20-058492 · doc4.xml · nonDerivative · entry 3 Shoemaker Daniel D · CIK 0001586892 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,091 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 12, 2020. F4 · price: Represents the weighted average sale price of the shares sold ranging from $51.96 to $52.88 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price. Read SEC document |
| November 16, 2020 Filed Nov 16, 2020 22:12 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon stock | 5,287 | $51.60 | $272,825.06 |
DisclosureSEC source: 0001209191-20-058492 · doc4.xml · nonDerivative · entry 2 Shoemaker Daniel D · CIK 0001586892 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,872 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 12, 2020. F3 · price: Represents the weighted average sale price of the shares sold ranging from $50.95 to $51.93 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price. Read SEC document |
| November 16, 2020 Filed Nov 16, 2020 22:12 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon stock | 4,932 | $50.37 | $248,406.59 |
DisclosureSEC source: 0001209191-20-058492 · doc4.xml · nonDerivative · entry 1 Shoemaker Daniel D · CIK 0001586892 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,159 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 12, 2020. F2 · price: Represents the weighted average sale price of the shares sold ranging from $49.91 to $50.90 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price. Read SEC document |
| September 14, 2020 Filed Sep 16, 2020 20:01 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon stock | 5,713 | $37.12 | $212,073.99 |
DisclosureSEC source: 0001209191-20-050681 · doc4.xml · nonDerivative · entry 3 Shoemaker Daniel D · CIK 0001586892 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,091 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 12, 2020. F4 · price: Represents the weighted average sale price of the shares sold ranging from $36.69 to $37.51 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price. Read SEC document |
| September 14, 2020 Filed Sep 16, 2020 20:01 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon stock | 17,887 | $36.11 | $645,908.51 |
DisclosureSEC source: 0001209191-20-050681 · doc4.xml · nonDerivative · entry 2 Shoemaker Daniel D · CIK 0001586892 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,804 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 12, 2020. F3 · price: Represents the weighted average sale price of the shares sold ranging from $35.68 to $36.65 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price. Read SEC document |
| September 14, 2020 Filed Sep 16, 2020 20:01 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon stock | 1,400 | $35.40 | $49,557.06 |
DisclosureSEC source: 0001209191-20-050681 · doc4.xml · nonDerivative · entry 1 Shoemaker Daniel D · CIK 0001586892 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141,691 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 12, 2020. F2 · price: Represents the weighted average sale price of the shares sold ranging from $34.68 to $35.67 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price. Read SEC document |
| January 08, 2020 Filed Jan 10, 2020 21:01 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | GrantStock Option (right to buy) · Derivative | 90,000 | Not disclosed Strike: $21.99 | Not disclosed |
DisclosureSEC source: 0001209191-20-003025 · doc4.xml · derivative · entry 3 Shoemaker Daniel D · CIK 0001586892 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires 2030-01-08 F5 · price: Not applicable. F4 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in 48 equal monthly installments beginning on February 1, 2020 such that this option is fully exercisable on January 1, 2024. Read SEC document |
| January 08, 2020 Filed Jan 10, 2020 21:01 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon Stock | 5,700 | $20.70 | $117,986.01 |
DisclosureSEC source: 0001209191-20-003025 · doc4.xml · nonDerivative · entry 2 Shoemaker Daniel D · CIK 0001586892 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,091 F2 · shares: Required number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of 15,000 shares of Common Stock underlying RSUs granted to the reporting person on January 7, 2019. This sale was made pursuant to an irrevocable election on November 20, 2019 by the reporting person to satisfy tax withholding obligations through a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.38 to $20.8850 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 08, 2020 Filed Jan 10, 2020 21:01 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | GrantCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-003025 · doc4.xml · nonDerivative · entry 1 Shoemaker Daniel D · CIK 0001586892 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,791 F1 · security: Award of restricted stock units ("RSUs") that vests with respect to 1/4 of the underlying shares on each of January 8, 2021, January 8, 2022, January 8, 2023, and January 8, 2024. This grant is subject to an accelerated vesting upon a change of control of the Issuer and in the event of termination of employment under certain circumstances following a change of control of the Issuer. Read SEC document |
| December 30, 2019 Filed Jan 2, 2020 21:01 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | Exercise / conversionStock Option (right to buy) · Derivative | 25,000 | Not disclosed Strike: $2.90 | Not disclosed |
DisclosureSEC source: 0001209191-20-000242 · doc4.xml · derivative · entry 4 Shoemaker Daniel D · CIK 0001586892 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,800 Underlying: Common Stock · 25,000 shares Expires 2026-01-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 20, 2018 and modified on December 10, 2018. F4 · price: Not applicable. F3 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in 48 equal monthly installments beginning on February 8, 2016 such that this option is fully exercisable on January 8, 2020. Read SEC document |
| December 30, 2019 Filed Jan 2, 2020 21:01 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon Stock | 100 | $20.34 | $2,034.00 |
DisclosureSEC source: 0001209191-20-000242 · doc4.xml · nonDerivative · entry 3 Shoemaker Daniel D · CIK 0001586892 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,791 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 20, 2018 and modified on December 10, 2018. Read SEC document |
| December 30, 2019 Filed Jan 2, 2020 21:01 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon Stock | 24,900 | $19.49 | $485,393.13 |
DisclosureSEC source: 0001209191-20-000242 · doc4.xml · nonDerivative · entry 2 Shoemaker Daniel D · CIK 0001586892 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,891 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 20, 2018 and modified on December 10, 2018. F2 · price: Represents the weighted average sale price of the shares sold ranging from $19.21 to $20.08 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price. Read SEC document |
| December 30, 2019 Filed Jan 2, 2020 21:01 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | Exercise / conversionCommon Stock | 25,000 | $2.90 | $72,500.00 |
DisclosureSEC source: 0001209191-20-000242 · doc4.xml · nonDerivative · entry 1 Shoemaker Daniel D · CIK 0001586892 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,791 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 20, 2018 and modified on December 10, 2018. Read SEC document |
| October 15, 2019 Filed Oct 16, 2019 20:04 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon Stock | 11,800 | $14.29 | $168,592.50 |
DisclosureSEC source: 0001209191-19-053272 · doc4.xml · nonDerivative · entry 1 Shoemaker Daniel D · CIK 0001586892 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,791 F1 · shares: Required number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of 33,000 shares of Common Stock underlying restricted stock units ("RSUs") granted to the reporting person on October 15, 2015. This sale was made pursuant to an irrevocable election on December 19, 2018 by the reporting person to satisfy tax withholding obligations through a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.94 to $14.59 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: All remaining shares of Common Stock held by the reporting person are subject to the terms of a lock-up agreement with Jefferies LLC and Citigroup Global Markets Inc. (the "Representatives"), as representatives of the underwriters in the Company's public offering pursuant to a prospectus supplement dated September 11, 2019, pursuant to which the reporting person agreed, without the prior written consent of the Representatives, and subject to limited exceptions, not to sell, offer to sell, contract to sell or lend, effect any short sale, pledge, hypothecate or grant any security interest in, or otherwise transfer or dispose of, any shares of Common Stock, either directly or indirectly. Read SEC document |
| June 27, 2019 Filed Jun 28, 2019 20:02 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | Exercise / conversionStock Option (right to buy) · Derivative | 12,500 | Not disclosed Strike: $2.90 | Not disclosed |
DisclosureSEC source: 0001209191-19-039461 · doc4.xml · derivative · entry 3 Shoemaker Daniel D · CIK 0001586892 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,800 Underlying: Common Stock · 12,500 shares Expires 2026-01-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 20, 2018 and modified on December 10, 2018. F4 · price: Not applicable. F3 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in 48 equal monthly installments beginning on February 8, 2016 such that this option is fully exercisable on January 8, 2020. Read SEC document |
| June 27, 2019 Filed Jun 28, 2019 20:02 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon Stock | 12,500 | $20.21 | $252,610.00 |
DisclosureSEC source: 0001209191-19-039461 · doc4.xml · nonDerivative · entry 2 Shoemaker Daniel D · CIK 0001586892 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,591 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 20, 2018 and modified on December 10, 2018. F2 · price: Represents the weighted average sale price of the shares sold ranging from $19.65 to $20.47 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price. Read SEC document |
| June 27, 2019 Filed Jun 28, 2019 20:02 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | Exercise / conversionCommon Stock | 12,500 | $2.90 | $36,250.00 |
DisclosureSEC source: 0001209191-19-039461 · doc4.xml · nonDerivative · entry 1 Shoemaker Daniel D · CIK 0001586892 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,091 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 20, 2018 and modified on December 10, 2018. Read SEC document |
| March 28, 2019 Filed Mar 29, 2019 20:01 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | Exercise / conversionStock Option (right to buy) · Derivative | 12,500 | Not disclosed Strike: $2.90 | Not disclosed |
DisclosureSEC source: 0001209191-19-021717 · doc4.xml · derivative · entry 3 Shoemaker Daniel D · CIK 0001586892 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,300 Underlying: Common Stock · 12,500 shares Expires 2026-01-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 20, 2018 and modified on December 10, 2018. F4 · price: Not applicable. F3 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in 48 equal monthly installments beginning on February 8, 2016 such that this option is fully exercisable on January 8, 2020. Read SEC document |
| March 28, 2019 Filed Mar 29, 2019 20:01 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon Stock | 12,500 | $16.94 | $211,702.50 |
DisclosureSEC source: 0001209191-19-021717 · doc4.xml · nonDerivative · entry 2 Shoemaker Daniel D · CIK 0001586892 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,591 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 20, 2018 and modified on December 10, 2018. F2 · price: Represents the weighted average sale price of the shares sold ranging from $16.71 to $17.30 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price. Read SEC document |
| March 28, 2019 Filed Mar 29, 2019 20:01 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | Exercise / conversionCommon Stock | 12,500 | $2.90 | $36,250.00 |
DisclosureSEC source: 0001209191-19-021717 · doc4.xml · nonDerivative · entry 1 Shoemaker Daniel D · CIK 0001586892 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,091 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 20, 2018 and modified on December 10, 2018. Read SEC document |
| January 07, 2019 Filed Jan 9, 2019 21:01 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | GrantStock Option (right to buy) · Derivative | 135,000 | Not disclosed Strike: $16.55 | Not disclosed |
DisclosureSEC source: 0001209191-19-003019 · doc4.xml · derivative · entry 2 Shoemaker Daniel D · CIK 0001586892 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,000 Underlying: Common Stock · 135,000 shares Expires 2029-01-06 F3 · price: Not applicable. F2 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in 48 equal monthly installments beginning on February 1, 2019 such that this option is fully exercisable on January 1, 2023. Read SEC document |
| January 07, 2019 Filed Jan 9, 2019 21:01 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | GrantCommon Stock | 45,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-003019 · doc4.xml · nonDerivative · entry 1 Shoemaker Daniel D · CIK 0001586892 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,591 F1 · security: Award of Restricted Stock Units that vests with respect to 1/3 of the underlying shares on each of January 7, 2020, January 7, 2021, and January 7, 2022. This grant is subject to an accelerated vesting upon a change of control of the Issuer and in the event of termination of employment under certain circumstances following a change of control of the Issuer. Read SEC document |
| January 16, 2018 Filed Jan 17, 2018 21:05 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | GrantStock Option (right to buy) · Derivative | 186,000 | Not disclosed Strike: $6.55 | Not disclosed |
DisclosureSEC source: 0001209191-18-003919 · doc4.xml · derivative · entry 1 Shoemaker Daniel D · CIK 0001586892 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 186,000 Underlying: Common Stock · 186,000 shares Expires 2028-01-15 F2 · price: Not applicable. F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in 48 equal monthly installments beginning on February 16, 2018 such that this option is fully exercisable on January 16, 2022. Read SEC document |
| October 16, 2017 Filed Oct 17, 2017 20:04 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon Stock | 700 | $4.08 | $2,856.00 |
DisclosureSEC source: 0001209191-17-057147 · doc4.xml · nonDerivative · entry 2 Shoemaker Daniel D · CIK 0001586892 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,591 F1 · shares: Required number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of 33,000 shares of Common Stock underlying restricted stock units ("RSUs") granted to the reporting person on October 15, 2015. This sale was made pursuant to an irrevocable election by the reporting person to satisfy tax withholding obligations through a "sell to cover"transaction and does not represent a discretionary trade by the reporting person. F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.97 to $4.17 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: Includes previously reported shares of Common Stock underlying RSUs granted to the reporting person, which are subject to certain vesting conditions. Read SEC document |
| October 13, 2017 Filed Oct 17, 2017 20:04 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon Stock | 12,525 | $3.86 | $48,346.50 |
DisclosureSEC source: 0001209191-17-057147 · doc4.xml · nonDerivative · entry 1 Shoemaker Daniel D · CIK 0001586892 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,291 F1 · shares: Required number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of 33,000 shares of Common Stock underlying restricted stock units ("RSUs") granted to the reporting person on October 15, 2015. This sale was made pursuant to an irrevocable election by the reporting person to satisfy tax withholding obligations through a "sell to cover"transaction and does not represent a discretionary trade by the reporting person. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.52 to $4.08 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: Includes previously reported shares of Common Stock underlying RSUs granted to the reporting person, which are subject to certain vesting conditions. Read SEC document |
| January 04, 2017 Filed Jan 6, 2017 21:02 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | GrantStock Option (right to buy) · Derivative | 150,000 | Not disclosed Strike: $2.73 | Not disclosed |
DisclosureSEC source: 0001209191-17-002630 · doc4.xml · derivative · entry 1 Shoemaker Daniel D · CIK 0001586892 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2027-01-03 F2 · price: Not applicable. F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in 48 equal monthly installments beginning on February 4, 2017 such that this option is fully exercisable on January 4, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.